China Biotech Services Holdings Limited provided earnings guidance for the three months ended 31 March 2022. The Group is expected to record a net profit attributable to the owners of the Company ("Net Profit") of not less than HKD 34,000,000 for the 2022 First Quarter Period as compared with that of approximately HKD 1,819,000 recorded for the corresponding period in 2021. It represented an increase of Net Profit for more than 17.69 times on a year-on-year basis.

The Board considers that such an increase of the Net Profit for 2022 first quarter of Period was mainly attributable to the robust demands for rapid antigen test kits and COVID-19 testing services during the period due to the raging fifth wave of COVID-19 pandemic.